Jaroslav Malý

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9521961/publications.pdf

Version: 2024-02-01

686830 610482 67 640 13 24 citations h-index g-index papers 73 73 73 943 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. European Journal of Endocrinology, 2010, 163, 645-650.	1.9	98
2	Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. Thrombosis and Haemostasis, 2010, 103, 736-748.	1.8	86
3	Prothrombotic changes due to an increase in thyroid hormone levels. European Journal of Endocrinology, 2015, 172, 537-542.	1.9	43
4	Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis, 2008, 197, 264-270.	0.4	36
5	Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: A series of four cases. Journal of Clinical Apheresis, 2012, 27, 215-220.	0.7	35
6	The importance of rheological parameters in the therapy of microcirculatory disorders. Clinical Hemorheology and Microcirculation, 2009, 42, 37-46.	0.9	28
7	Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2014, 158, 511-517.	0.2	25
8	Safety and Tolerability of Long Lasting LDL-apheresis in Familial Hyperlipoproteinemia. Therapeutic Apheresis and Dialysis, 2007, 11, 9-15.	0.4	23
9	High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplantation, 2008, 41, 51-54.	1.3	19
10	Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. Acta Ophthalmologica, 2011, 89, 463-471.	0.6	19
11	Cardiac Troponin I Seems to Be Superior to Cardiac Troponin T in the Early Detection of Cardiac Injury Associated with Anthracycline Treatment. Onkologie, 2008, 31, 12-12.	1.1	16
12	Prevalence of hypercoagulable disorders in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2014, 49, 287-294.	0.6	14
13	Chronic thromboembolic pulmonary hypertension after the first episode of pulmonary embolism? How often?. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2016, 160, 125-129.	0.2	14
14	Venous Thromboembolism in Young Female While on Oral Contraceptives: High Frequency of Inherited Thrombophilia and Analysis of Thrombotic Events in 400 Czech Women. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 567-573.	0.7	13
15	Activity of thrombocytes as a marker of sufficient intensity of LDL-apheresis in familial hypercholesterolaemia. Transfusion and Apheresis Science, 2004, 30, 83-87.	0.5	10
16	Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. European Journal of Haematology, 2007, 79, 305-309.	1.1	9
17	The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. Journal of Thrombosis and Thrombolysis, 2008, 26, 154-158.	1.0	8
18	Extracorporeal LDL cholesterol elimination (25 years of experience in CZ). Atherosclerosis Supplements, 2009, 10, 17-20.	1.2	8

#	Article	IF	Citations
19	Significant change in ZAPâ€₹0 expression during the course of chronic lymphocytic leukemia. European Journal of Haematology, 2010, 84, 513-517.	1.1	8
20	Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features. Hematology, 2010, 15, 210-214.	0.7	8
21	Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells. Neoplasma, 2011, 58, 140-145.	0.7	8
22	Risk of Thrombosis in Patients Homozygous and Heterozygous for Factor V Leiden in the East Bohemian Region. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 87-89.	0.7	7
23	The decrease of mean platelet volume after extracorporeal LDL-cholesterol elimination. Atherosclerosis Supplements, 2013, 14, 77-81.	1.2	7
24	Prevalence of inherited thrombophilia in young thrombosis patients from the East Bohemian region. Blood Coagulation and Fibrinolysis, 2002, 13, 569-573.	0.5	6
25	Glycogen phosphorylase BB could be a new biomarker for detection of cardiac toxicity during hematopoietic cell transplantation for hematological malignancies. Bone Marrow Transplantation, 2010, 45, 1123-1124.	1.3	6
26	The importance of rheological parameters in the therapy of the dry form of age-related macular degeneration with rheohaemapheresis. Clinical Hemorheology and Microcirculation, 2012, 50, 245-255.	0.9	6
27	The Purple Toe Syndrome in Female With Factor V Leiden Mutation Successfully Treated With Enoxaparin. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 100-102.	0.7	6
28	The Risk of Infection Transmission from Blood Progenitor Cell Concentrates. Journal of Hematotherapy and Stem Cell Research, 2003, 12, 161-164.	1.8	5
29	Prevention of infection transmission during stem cell transplantation. Folia Microbiologica, 2006, 51, 609-613.	1.1	5
30	New biomarkers of myocardial injury and assessment of cardiac toxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Clinical Chemistry and Laboratory Medicine, 2008, 46, 148-9.	1.4	5
31	Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	5
32	Experience with extracorporeal elimination therapy in myasthenia gravis. Transfusion and Apheresis Science, 2011, 45, 251-256.	0.5	5
33	Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia. Bratislava Medical Journal, 2013, 114, 708-710.	0.4	5
34	Hemostatic changes before and during electrophysiologic study and radiofrequency catheter ablation. International Journal of Hematology, 2011, 93, 452-457.	0.7	4
35	Use of Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry to Demonstrate Decreased Serum Statin Levels after Extracorporeal LDL-Cholesterol Elimination. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	4
36	Good Short-Term but not Long-Term Reproducibility of the Antiplatelet Efficacy Laboratory Assessment. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 174-180.	0.7	4

#	Article	IF	CITATIONS
37	Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. Neoplasma, 2014, 62, 585-592.	0.7	4
38	Potential risk of infection transmission during storage and transplantation of hematological progenitor cells. Safety assurance. Folia Microbiologica, 2003, 48, 399-402.	1.1	3
39	Optimization of the therapeutic procedure during LDL-apheresis—a computerized model. Transfusion and Apheresis Science, 2005, 32, 149-156.	0.5	3
40	Primary hemostasis in patients treated with LDL-apheresis for severe familiar hypercholesterolemia: A prospective pilot trial using PFA-100 analysis to rationalize therapeutic LDL-apheresis procedure. Hematology, 2007, 12, 571-576.	0.7	3
41	Cascade Filtration in the Therapy of the Dry Form of Age-related Macular Degeneration. Therapeutic Apheresis and Dialysis, 2009, 13, 453-454.	0.4	3
42	NT-proBNP levels on admission predict pulmonary hypertension persistence in patients with acute pulmonary embolism. Cor Et Vasa, 2012, 54, e27-e31.	0.1	3
43	Prognostic value of mean platelet volume in patients after acute coronary syndrome. Anatolian Journal of Cardiology, 2015, 15, 31-32.	0.4	3
44	Meeting Report: The XXVth Slovak-Czech Conference on Hemostasis and Thrombosis (with) Tj ETQq0 0 0 rgBT 117-120.	/Overlock : 1.5	10 Tf 50 467 3
45	ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES. Acta Medica (Hradec Kralove), 2014, 57, 157-161.	0.2	2
46	Intravascular ultrasound study of the effect of \hat{l}^2 -emitting (55Co) stents on vascular remodeling and intimal proliferation. Catheterization and Cardiovascular Interventions, 2004, 61, 320-325.	0.7	1
47	W16-P-053 Computer aided optimization and standardization of the procedures in lipid lowering immunotherapy. Atherosclerosis Supplements, 2005, 6, 114.	1.2	1
48	Long-term health outcome and mortality evaluation after invasive coronary treatment using drug-eluting stents: HOME DES registry. Coronary Artery Disease, 2007, 18, 577-581.	0.3	1
49	Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary?. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 150138.	0.2	1
50	Clinical use of reverse isolation in a protected Environment. Folia Microbiologica, 1979, 24, 88-95.	1.1	0
51	2.P.321 Smoking, platelets and risk of thrombosis. Atherosclerosis, 1997, 134, 183.	0.4	0
52	4.P.117 Effect of a modified fasting on fibrinolytic capacity. Atherosclerosis, 1997, 134, 320.	0.4	0
53	Is Travelling a Risk Factor for Venous Thrombosis in Individuals with Factor V Leiden in Heterozygous Form?. , 2005, , 272-274.		0
54	W16-P-008 Assessment of absorber efficacy during LDL-apheresis. Atherosclerosis Supplements, 2005, 6, 102.	1.2	0

#	Article	IF	CITATIONS
55	T07-P-002 LDL-lowering immunoapheresis is well tolerated and safe procedure in familial hyperlipoproteinaemia. Atherosclerosis Supplements, 2005, 6, 171.	1.2	0
56	Th-P16:317 Performance of LDL-apheresis and its relation to haemostasis. Atherosclerosis Supplements, 2006, 7, 563.	1.2	0
57	PO3-65 DECREASED ATHEROGENIC LIPOPROTEINS LINKED TO AGE RELATED MACULAR DEGENERATION (ARD): IMPACT OF HAEMORHEOPHERESIS. Atherosclerosis Supplements, 2007, 8, 34.	1.2	0
58	Successful use of continuous infusion of FVII in urologic surgery. Haemophilia, 2008, 14, 637-638.	1.0	0
59	OUTCOME COMPARISON TO TAKE ADVANTAGE OF MODIFIED PLATELETS AGGREGATION AND PFA-100 ANALYSIS TO RATIONALIZE THERAPEUTIC LDL-APHERESIS PROCEDURE. Atherosclerosis Supplements, 2008, 9, 168-169.	1.2	0
60	Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia – the Retrospective Analysis. Biology of Blood and Marrow Transplantation, 2011, 17, S321.	2.0	0
61	P.1 Thromboprophylaxis in pregnancy in women with increased risk of venous thromboembolism. Thrombosis Research, 2011, 127, S129.	0.8	0
62	P.2 Cerebral venous thrombosis risk factors. Thrombosis Research, 2011, 127, S129.	0.8	0
63	Factor V and FVIII deficiency in a young Czech woman. Haemophilia, 2012, 18, e37.	1.0	0
64	Therapeutic plasma exchange in patients with neurologic diseases: One centre experience. Transfusion and Apheresis Science, 2013, 48, 145.	0.5	0
65	The Frequency of Venous Thromboembolism in Women with F V Leiden in Heterozygous Form from the East Bohemia Region in Association with Pregnancy and Puerperium Blood, 2004, 104, 4006-4006.	0.6	0
66	Potential uses of assessment of functional changes in primary hemostasis by the PFA-100 analyzer and modified assessment of platelet aggregation in rationalizing management of patients with familiar hypercholesterolemia treated by extracorporeal LDL-cholesterol elimination. Cor Et Vasa, 2007, 49, 303-311.	0.1	0
67	The Frequency of Venous Thromboembolism in Women with FV Leiden in Association with Pregnancy and Puerperium. , 2006, , 209-212.		0